Connected Prehabilitation Program During Neo Adjuvant Chemotherapy

Ovarian Cancer Clinical Trial

— TRAINING  

Official title:

Multicenter Randomized Study Comparing Neo Adjuvant Chemotherapy for Patients Managed for Ovarian Cancer With or Without a Connected Prehabilitation Program

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04451369
• Other study ID #: TRAINING-01-IPC 2018-039
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 2021
• Est. completion date: September 2027

Study information

• Verified date: May 2020
• Source: Institut Paoli-Calmettes
• Contact: Dominique GENRE, Dr
• Phone: +33 4 91 22 37 78
• Email: drci.up[@]ipc.unicancer.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

NACT is a heavy oncologic treatment, which can impair functional capacity, nutritional and emotional status. These three impairments are often ignored and not taken into account in the pre-therapeutic evaluations but are correlated with postoperative morbidity and mortality after major surgery.

Recently, a prehabilitation before surgery, including physical, nutritional and psycho-social support, has been defined. From a literature review, the maximum oxygen uptake (VO2 max) seems to constitute a strong evaluation factor reflecting physical fitness, easily measured with a cardiopulmonary exercise test (CPET) at maximal effort.

Several studies have shown beneficial effects of trimodal prehabilitation programs on postoperative functional capacity, return to daily activities and pain relief.

Home-based program and connected devices may improve the feasibility and the compliance to this program.

The hypothesis of this study is that performing a connected supervised home-based and patient-tailored multimodal prehabilitation program from diagnosis to surgery (with or without ERAS program) during NACRT, for patients managed for ovarian cancer, will limit physical fitness alteration and will positively affect postoperative outcomes.

Our study consists in an early and multidimensional (combining nutritional, physical, emotional and medical support) prehabilitation program during NACT for patients with ovarian cancer, in order to limit physical alteration before surgical treatment, and therefore improve postoperative outcomes. It will include a home-based prehabilitation program, in order to allow care access to all eligible patients.

Description:

The main objective will be to determine if a prehabilitation program during NACT, for patients treated for an advanced ovarian cancer will limit physical alteration before major abdomino-pelvic surgery, compared to a control group without prehabilitation program. The primary endpoint will be the comparison of the variation of VO2 max, between baseline and surgery, in the prehabilitation group vs control group: VO2 max will be measured with a cardiopulmonary exercise test (CPET) at maximal effort.

This prospective, multicentric randomized control trial will be conducted in 7 French comprehensive cancer Centers or University Hospital, in compliance with inclusion criteria. After an initial evaluation, patients will be randomized in two groups: Prehabilitation group (P group) and a Control group (C group).

For the P group, after baseline evaluation, we will be offering from diagnosis to surgery, during the NACT:

• A standardized, patient-tailored preoperative physical activity training program will be performed at home, from diagnosis to surgery. Supervision will be done with connected device (connected watches) and activity will be adapted,

• A nutritional care established in respect of the SFNEP-SFNCM guidelines. Nutritional support will be adapted by a dietician according to information transmitted daily (connected body fat weight scale),

• A psychological support with coping strategies.

For the C group: Patients with ovarian cancer will undergo NACT after baseline evaluation without prehabilitation program.

After NACT, for both groups, major abdomino-pelvic surgery will be done with or without ERAS pathway, according to the practice in each center.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 136
• Est. completion date: September 2027
• Est. primary completion date: September 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient must have signed the written consent,

2. Age = 18 years,

3. Patient with advanced ovarian cancer (AOC), FIGO Stage III - IV, undergoing surgery,

4. Patient with neo adjuvant chemotherapy (min 3 cycles, max 6 cycles),

5. Capability to perform a cardiopulmonary exercise test (CPET)

6. Patient affiliated to the national "Social Security" regimen or beneficiary of this regimen.

Exclusion Criteria:

1. Patient with cognitive impairment,

2. Pregnancy,

3. Neoadjuvant treatment contraindications,

4. Physical adapted activity program contraindication,

5. No possibility to have access to connected devices or do not have a smartphone or a computer

6. Patient deprived of liberty or placed under the authority of a tutor,

7. Patient considered socially or psychologically unable to comply with the procedure and the required medical follow-up.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Other:
• Prehabilitation program
physical, nutritional and psycho-social supports before surgery

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Institut Paoli-Calmettes

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine if a prehabilitation program during NACT, for patient managed with advanced ovarian cancer (AOC) will limit physical alteration before surgery, compared to a control group without prehabilitation program (change between 3 timepoints).	CHANGE of VO2 max between baseline (inclusion) and surgery (preoperative), in the prehabilitation group vs control group. VO2 max will be measured during a cardiopulmonary exercise test (CPET).	baseline, 15 days before surgery and 3 moths before surgery
Secondary	to compare physical outcomes between both groups	o International Physical Activity Questionnaire (IPAQ) , administered at inclusion and at the time of surgery and after surgery	baseline, before surgery, and 3 months after surgery
Secondary	to compare physical outcomes between both groups	Muscular strength evaluated with dynamometer (brachial biceps)	baseline, before surgery, and 3 months after surgery
Secondary	to compare Quality of Life, emotional outcomes between both groups	Psychological status evaluated by the Hospital Anxiety and Depression Scale (HADS) (Annex 2)	baseline, before surgery, and 3 months after surgery
Secondary	to compare Quality of Life, emotional outcomes between both groups	Cancer related quality of life (QoL) evaluated by using the self-reported European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (QLQ-C30) (Annex 3)	baseline, before surgery, and 3 months after surgery
Secondary	to compare Quality of Life, emotional outcomes between both groups	Motivation evaluated by a free interview and a coping strategy.	baseline, before surgery, and 3 months after surgery
Secondary	to compare nutritional outcomes between both groups	Change Body Mass Index (BMI)	baseline, before surgery, and 3 months after surgery
Secondary	to compare nutritional outcomes between both groups	Muscle mass evaluated with the Computed tomography-derived	baseline, before surgery, and 3 months after surgery
Secondary	to compare nutritional outcomes between both groups	skeletal muscle index measured by skeletal muscle mass cross-sectional area at L3/height2	baseline, before surgery, and 3 months after surgery
Secondary	to compare nutritional outcomes between both groups	Weight in kg	baseline, before surgery, and 3 months after surgery
Secondary	to compare Surgical Morbidity rate between both groups	Clavien-Dindo classification	at day 30 and day 90 (3 months) after surgery
Secondary	to compare Surgical Morbidity rate between both groups	NCI-CTCAE v 5.0 classification	at day 30 and day 90 (3 months) after surgery